tcsc3286 WAY-262611

WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate with an EC₅₀ of 0.63 μM in TCF-Luciferase assay.

IC50 & Target: EC50: 0.63 μM (β-Catenin)^[1]

In Vitro: WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility^[1].

In Vivo: WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt β-catenin pathway and most likely through inhibition of Dkk-1^[1].